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In English
The Ministry of Social Affairs and Health published its new
strategy in June.1 The strategic aims of pharmaceutical
services are discussed in a couple of sections, mainly focusing
on ways for improving the cost-effectiveness of pharmaceuti-
cal therapy and distribution of medicines. The ways suggest-
ed include reviewing the problems involved with the two-
channel financing of medicinal products , drawing up guide-
lines for these, developing the refund system of medicines
and reforming the pharmacy system. The aim is to secure a
nation-wide distribution of medicines and pharmaceutical
information supplied by pharmacies to the consumers.
The strategy of the Ministry of Social Affairs and Health
also sets concrete targets for pharmaceutical services, which
is positive, and in addition especially for issues other than
those relating to cost-cutting exercises alone. Medicines  are
such an important part of securing modern health services
that issues ought to be examined from other viewpoints, too,
not only from the viewpoint of financing. Measures need to
be taken, for example, to improve the quality of
pharmacotherapy for the elderly.
Ignoring the strategies of the state authorities, a small but
prominent group of pharmacists is on the lookout for new
models of action emphasising the principles of image build-
ing along the lines with daily grocery businesses. Firms
known as pharmacy kiosks, for example, have been built
within pharmacies. The aim is to set up an arrangement
which would allow any freely traded goods, nicotine prod-
ucts, for example, to be sold via a separate firm within the
pharmacy. An innovative concept, that of a pharmacy mar-
ket, has also been launched. Pharmacy chains have been a
discussion topic for a long while. These issues are not
promoted so much by pharmacies with a lower turnover, but
generally by larger-than-medium sized pharmacies.
It feels odd that some pharmacists should want to
obscure the professional role of pharmacies by emphasising
elements of marketing and competition. Why should they
want to do that? The question is genuine, particularly, in
view of the fact that health issues have been repeatedly
emphasised in the state authorities’ health- and medico-
political principles. Pharmacists operating within the
safeguard of the state authorities’ pharmacy licences and reg-
ulations are apparently not content with focusing on health,
but would like to use any means available to increase their
business turnover.
Behind the build-up of chains and the development of
kiosk firms and markets, is there a plan to raise the turnover
and gain advantage over a situation where the Finnish phar-
macy licensing system would be dismantled and the retail
sale of medicinal products opened up to competition? Some
pharmacists would probably prefer it if Finland were to fol-
low in the footsteps of Norway, where, a couple of years ago,
a number of pharmacists were allowed to sell their pharma-
cies to pharmaceutical wholesale chains, evidently at a good
price. I do not believe that this would happen in Finland,
irrespective of whatever direction the development of the
pharmacy system takes. Few would accept a situation where
the licences under state regulation became objects of market
speculation. On granting the licences the state has once
already guaranteed a relatively good source of  business to
the pharmacists.
The government programme after the elections next
spring ought to contain clear principles and guidelines for
the development of pharmacy operations. If the present
principles, with their emphases on health policies, nation-
wide distribution of medicinal products, cost-effectiveness,
pharmaceutical information and professional pharmaceutical
services, are to be followed in the end, the result should be
that pharmacies maintain their status as pharmacies. Other-
wise, the markets will rule, and control of the increase in the
sales and consumption of medicinal products will become
even more difficult than before.
1 Strategies for Social Protection 2015. Towards a socially and
economically sustainable society. STM 2006
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A previously healthy 10-year-old girl
received a course of amoxicillin in June
2006 for the treatment of redness on the
left ear lobe which was suspected of hav-
ing been due to borreliosis and which
subsequently healed well.
A couple of weeks later on 20.7. the
girl experienced an onset of headache,
neck stiffness, numbness in the right
cheek, ear ache and mild fever. On 21.7.
the ears were normal and the CRP was
under 5 mg/l.
On 24.7. the patient was admitted
to hospital owing to left-sided facial
nerve paralysis. The clinical picture was
that of meningitis. Elevated leukocyte
levels in the spinal cord fluid were also
indicative of meningitis (mononuclear
leucosyte count 222 E6/l and polymor-
phonuclear granulocyte count 76 E6/l).
The patient also suffered from an
annoying dry cough. There was no ear
inflammation present, and this was con-
firmed on paracentesis.
Suspected possible causes of the
facial nerve paralysis and meningitis
were 1) borreliosis, because of the previ-
ously exhibited redness on the ear lobe,
2) mycoplasma infection on account of
the dry cough and spinal cord fluid
finding, and 3) herpes virus infection on
account of the increased vascular perfu-
sion in the prosence-phalon detected on
single photon emission computed
tomography (SPECT).
The medication introduced on the
day of admission included intravascular
aciclovir therapy to treat any herpes
infection present, oral roxithromycin for
the treatment of any mycoplasma infec-
tion, and intravascular ceftriaxone for
the treatment of borreliosis (2 g = 77
mg/kg x 1). Aciclovir therapy was with-
drawn after a week once the PCR test
for herpes in the cerebrospinal fluid was
reported to be negative. Roxithromycin
therapy was discontinued on 2.8. once
elevation of the serum mycoplasma anti-
bodies could no longer be detected.
The girl had consumed French fries
in the evening following the sixth dose
of ceftriaxone. During the subsequent
night, she was struck by a severe attack
of pain in the upper abdomen
resembling a biliary colic. This was
quickly relieved by intravascular admin-
istration of metamizol (Litalgin). The
severe colicky pain recurred again
following a subsequent dose of ceftriax-
one, and the treatment of suspected bor-
reliosis was therefore continued by the
administration of oral amoxicillin.
An ultrasonography of the upper
abdomen on 30.7. revealed an
abundance of small gallstones in the
gallbladder, which left an acoustic shad-
ow. The gallbladder or biliary ducts did
not contain any sludge. The serum ala-
nine transferase and glutamyl transferase
values were elevated, indicating a biliary
colic. Liver enzyme and bilirubin levels
remained normal. The patient’s blood
count was normal, as were the serum
lipid levels. 
On the third and fifth days after the
withdrawal of ceftriaxone therapy the
patient suffered from attacks of pain the
upper abdomen following a meal despite
her attempts to adhere to a diet
designed for biliary patients. On that
occasion the pain was located below the
left costal arch, which was uncharacteris-
tic for a biliary patient and more resem-
bled gastrointestinal pain. The patient
feared she might have another biliary
colic and carefully reported all stomach
pains in order to receive analgetic med-
ication early enough. Stomach pains did
not recur after the introduction of
omeprazole therapy.
A biliary and pancreatic duct MRI
on 7.8. was aimed at revealing any
anomalies in the ducts prior to the
surgery which was planned; however, no
anomalies were found. The gallstones
had disappeared from the gallbladder
and were not detected in a subsequent
ultrasonography of the upper abdomen
on 8.8. Cholelithectomy was conseq-
uently cancelled.
Influenzas A and B occurring simul-
taneously often cause similar symptoms.
Influenza virus may also cause brain
symptoms with cases of resultant ence-
phalopathy, as described in children in
Japan.
The virus antibodies found in the
patient’ serum disclosed a distinct eleva-
tion of the influenza B virus titre,
whereas the Borrelia-specific antibodies
in the cerebrospinal fluid and serum
were found to be negative, as was the
PCR detection of Borrelia in the
cerebrospinal fluid. The redness on the
ear lobe treated at the beginning of the
summer was perhaps not caused by Bor-
relia bacteria after all. The facial nerve
paralysis started to improve about two
weeks after the manifestation of the
symptoms of paralysis.
Borrelia bacteria are readily suspect-
ed as being the cause of even undefined
redness of the skin, especially if the
patient suffers from nervous system
symptoms. For the treatment of dissemi-
nated Borrelia infection in children a 2-
week course of ceftriazone is given,
while the alternative therapies
considered include doxycycline and
amoxicillin. Doxycycline is associated
with skin reactions caused by sunlight.
As we have seen, our patient had previ-
ously received a course of amoxicillin.
The diagnosis of borreliosis requires
patience and wise decision-making in
the introduction of antibiotic therapies
in order to avoid the administration of
unnecessary antibiotic treatment and the
associated adverse reactions.
My observation of an adverse drug reaction 
Ceftriaxone and biliary colic in a school girl
In English
Kaisu Antila ADR News
Pediatrician
Pohjois-Karjala Central Hospital
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Ceftriaxone and biliary symptoms
In English
According to various studies, abnormal
ultrasonographic findings have been
associated with the use of ceftriaxone
in 25–50% of the patients. This type
of adverse reaction was first described
in children about 20 years ago and
later also in adult patients. The
patients are often symptom-free and an
ultrasonographic finding of “sludge” is
made. This occurs on the 9th day of
treatment on average, and disappears
by itself within a couple of weeks fol-
lowing discontinuation of the therapy.
Findings of actual gallstones have been
made more rarely.
The adverse drug reaction register
of the National Agency for Medicines
in Finland has accumulated a total of
27 reports of reactions associated with
ceftriaxone; five of these include an
adverse reaction associated with the
gallbladder. The Table below includes
more details about the cases. Four of
the reports involved a paediatric
patient and one involved a 32-year-old
female.
Annikka Kalliokoski
Patient Indication Duration Adverse Ultrasonic Recovery
of ceftriaxone reaction finding
therapy 
prior to
symptom
4-year-old boy Suspected meningitis 3 days Gallstones Biliary duct wall oedema; Recovered;  no gallstones
two large gallstones detected on ultrasono-
graphy about 1 month later
5-year-old boy Meningitis 5 days Gallstones Gallstones Not known
10-year-old girl* Suspected Borrelia, 6 days Gallstones Gallstones Recovered; no gallstones
facial nerve paralysis detected on ultrasono-
graphy about 1 week later
16-year-old boy Meningitis 8 days Biliary pain Condensation of echo Recovered; a normal 
in the gallbladder; finding on ultrasonography
a stone or gravel about 2.5 months later
32-year-old female Pneumonia 2 days after Upper abdominal  Gravel at the bottom of Recovered
the completion pain the gallbladder. Same 
of a 10-day course finding on MRI
* the patient in the case history
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In English
Improved functionality of the medicinal products database
The National Agency for Medicines
(NAM) in Finland has reorganised its
drug information services by improv-
ing the search facility of summaries of
product characteristics (SPC) and
package leaflets (PL) on its website.
On its website NAM has since
spring 2002 published SPCs and PLs
of marketing authorisations approved
by it via the national or mutual recog-
nition procedure. In 2003 it became
mandatory for the marketing authori-
sation holders to submit their texts for
publication electronically to NAM.
The website of NAM nowadays
includes about 4,400 published SPCs
and 3,300 PLs. In August, technical
changes were made in the services to
improve their ease of use.
The search functions have been
improved, together with other reorgan-
isation, and plenty of alternatives to
vary them are offered. Anybody look-
ing for information can write either a
word or part of a word in all the search
fields and get a combined search result.
The search function is initiated simply
by pressing Enter even if several search
conditions are given.
Owing to the technical improv-
ements made it has also been possible
to simplify the publication process at
NAM, and the frequency of updating
of SPCs and PLs on the website can be
increased in future as a result.
In addition to the improved ease of
use, the marketing authorisation hold-
ers can also benefit from the reorgani-
sation in the form of simplified
instructions for the composing of
SPCs. The new instructions for prepar-
ing SPCs are available on the website
of NAM. The instructions for prepar-
ing package leaflets have not changed.
NAM services relating to SPCs and
PLs provide the facilities to search for
the SPCs in Finnish and for the PLs in
Finnish and Swedish of marketing
authorisations approved via both the
national and the mutual recognition
procedures. The SPCs and PLs of
human, veterinary and herbal medici-
nal products are found separately.
The service is available at: 
http://www.laakelaitos.fi/laaketieto/
valmisteyhteenvedot/index.html 
The service is also available on NAM’s
English and Swedish webpages at:
http://www.nam.fi/english/medicines/
spc_pl_summaries/index.html
http://www.nam.fi/svenska/lakemedel/
spc_pl/index.html
The documents relating to medicinal
products with approved marketing
authorisation via the centralised proce-
dure are available at the EMEA web-
site: http://www.emea.europa.eu/htms/
human/epar/a-zepar.htm
This website also includes the SPCs
and PLs in Finnish among 19
European languages. 
Krista Leppänen
Translation Mervi Moisander
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In English
Finnish Statistics on
Medicines 2005
published
The book Finnish Statistics on Medicines
2005 by the National Agency for Medicines
and Social Insurance Institute has been pub-
lished. 
In 2005, total sales of medicines in Finland
were about EUR 2.4 billion. The growth of
medicinal costs was slower than before the
beginning of generic substitution. The
biggest part, 72%, was attributable to
prescription-only medicines in outpatient
care. In this group, the growth of sales was
3% less than in 2004. Social Insurance Insti-
tution paid reimbursements of medicines to
3.3 million people in Finland, altogether
EUR 1.1 billion, which was 6.1 % more than
in the previous year. 
Drug statistics can also be found on the
internet: www.nam.fi/english/medicines/drug
consumption/
and
www.kela.fi/in/internet/english.nsf/statistics.
The publication can be subscribed from the
address tilaukset@nam.fi or by phone: +358
(9) 47 334 289. 
